# Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing Breast-Conserving Surgery

Source: https://onco.cc/trials/nct07723469/  
OnCo record `nct07723469` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in triple-negative breast cancer, run by SURGE Therapeutics, not yet recruiting.

## Summary

Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing Breast-Conserving Surgery is a phase 3, randomised interventional study registered as NCT07723469 by SURGE Therapeutics, with a registry enrolment figure of 400 participants, started 2026-10 and due to reach its primary completion in 2034-10. Interventions recorded: BCS + SRG-514; BCS. Conditions listed: TNBC - Triple-Negative Breast Cancer. Triple-negative eligibility wording from the registry: "* Eligible participants will be adults (≥18 years old) who have a history of histologically confirmed diagnosis of TNBC (clinical stage II-III), except inflammatory breast cancer". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07723469
- Phase: 3
- Setting: A Randomized, Phase 3 Trial of SRG-514 Administered Intraoperatively to the Site of Tumor Resection in Patients Undergoing Breast-Conserving Surgery for Triple Negative Breast Cancer
- Sponsor: SURGE Therapeutics
- Enrolled: 400

## Sources

- ClinicalTrials.gov NCT07723469: https://clinicaltrials.gov/study/NCT07723469

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07723469.json